Cantor starts Satellos with an Overweight on DMD therapy potential

As previously reported, Cantor Fitzgerald analyst Yanni Souroutzidis initiated coverage of Satellos (MSLE) with an Overweight rating and no price target SAT-3247 is an oral pill designed to improve muscle regeneration in Duchenne muscular dystrophy, which the firm calls “a fundamentally different approach from existing therapies.” Current therapies try to reduce demand, but no approved therapy addresses the supply side and SAT-3247 “aims to be the first,” the analyst tells investors.